Abstract

Tuberculosis (TB) and human immunodeficiency virus (HIV) infection interfere and impact the pathogenesis phenomena of each other. Owing to atypical clinical presentations and diagnostic complications, HIV/TB co-infection continues to be a menace for healthcare providers. Although the increased access to highly active antiretroviral therapy (HAART) has led to a reduction in HIV-associated opportunistic infections and mortality, the concurrent management of HIV/TB co-infection remains a challenge owing to adverse effects, complex drug interactions, overlapping toxicities and tuberculosis -associated immune reconstitution inflammatory syndrome. Several hypotheses have been put forward for the exacerbation of tuberculosis by HIV and vice versa supported by immunological studies. Discussion on the mechanisms produced by infectious cofactors with impact on disease pathology could shed light on how to design potential interventions that could decelerate disease progression. With no vaccine for HIV and lack of an effective vaccine for tuberculosis, it is essential to design strategies against HIV–TB co-infection.

The immunopathogenesis underlying the symbiotic establishment of HIV-1/M. tuberculosis in the susceptible host remains to be understood better to design strategies ultimately to improve the quality of life of infected individuals.

The immunopathogenesis underlying the symbiotic establishment of HIV-1/M. tuberculosis in the susceptible host remains to be understood better to design strategies ultimately to improve the quality of life of infected individuals.

Introduction

The co-evolution of bacteria with their host has led to bidirectional evolutionary pressures, eventually leading to refinement of survival mechanisms in both species that culminate in symbiotic relationships (Vujkovic-Cvijin et al., 2013). Certain microorganisms, despite the co-evolution process, can cause life-threatening pathology and disease, especially in immunocompromised hosts (Kownhar et al., 2007; Muthu et al., 2006; Shankar et al., 2005, 2006a, b; Vignesh et al., 2008). Long before AIDS was first reported, it was known that measles virus could render individuals immunosuppressed (Coughlin et al., 2013), and that tuberculosis commonly occurred following an outbreak of measles. It is also known that following an episode of chickenpox (varicella zoster virus infection), secondary pulmonary bacterial infections can develop owing to an immunocompromised state engineered by herpes viruses (Dinleyici et al., 2012). In the individual host, the two pathogens, Mycobacterium tuberculosis and the HIV type 1 (HIV), appear to have great impact on each other, accelerating the deterioration of immune functions (WHO, 2008; Pawlowski et al., 2012). Tuberculosis remains a major global health menace and is the second most frequent cause of death due to infectious disease worldwide. Tuberculosis is reported to be encountered by one-third of the global population, of which about 10% develop active tuberculosis. According to the latest World Health Organization (WHO) estimates, there were c. 9 million new cases and 1.4 million tuberculosis deaths during 2011. In 2011, HIV-positive individuals accounted for 1.1 million (13%) of the 8.7 million people who developed tuberculosis worldwide (WHO, 2011). Of the individuals with tuberculosis who were tested for HIV, 23% were positive in 2011 (UNAIDS, 2012). Today, at least one-third of the 34 million people who are HIV-positive worldwide are infected with latent tuberculosis. Individuals co-infected with TB/HIV are reported to have an c. 21–34 times higher risk of developing active tuberculosis than those without HIV infection (WHO, 2011).

Mycobacterium tuberculosis is a highly evolved complex organism that affects primarily the respiratory tract, although disseminated lymphohematogenous infection can occur in immunocompromised subjects (Ray et al., 2013). Acquisition of M. tuberculosis infection is predominantly via inhalation of aerosolized bacilli into the respiratory tract. The alveolar macrophages patrolling the airways and Langerhans cells (immature dendritic cells (IDCs)) of the mucosal lining of the airways pick the bacilli, and process them along the route of transit to the regional lymph nodes to initiate the adaptive immune responses. However, the tubercle bacilli prevent fusion of the phagosomal compartment with the lysosome and replicate successfully within this vesicular niche (Vandal et al., 2009). The exact mechanism behind their retention in phagosomes remains unclear, but might depend on evasion of the acidic barriers within the endosomal vesicle via the bacilli's arabinogalactan mycolate lipoarabinomannan (LAM) complex (Wax-D)-enriched acid-fast cell-wall structures (Forrellad et al., 2013). Wax-D on the surface of the tubercle bacilli probably modifies the phagosome membrane and inhibits the trafficking processes that would normally enhance fusion of phagosomed with the lysosomal compartment (Dhiman et al., 2009; Forrellad et al., 2013). Bacterial establishment is also facilitated by exuberant accumulation of macrophages, fibroblasts, lymphocytes, DCs and neutrophils that form multinucleated giant cell-rich granulomas, which seek to limit replication of the bacilli (Dhiman et al., 2009). Nonetheless, M. tuberculosis persists within the granuloma, and any event that reduces the integrity of the granuloma will eventually reactivate the latent tuberculosis infection. This reactivation leads to lymphohematogenous dissemination, and onset of severe active tuberculosis marked by Ghon focus (involving hilar lymph nodes) and caseous necrosis, especially in the apical segment of lungs owing to poor air pumping mechanisms and lymphatic distribution (Tan et al., 2010).

HIV infection is acquired mainly via genital mucosal exposure where immature DCs pick the virus from mucosal sites, and disseminate the virus to the CD4+ coterie of T cells, eventually leading to the onset of T-cell depletion and opportunistic infections (OIs) and neoplasms (Kumarasamy et al., 2005; Vignesh et al., 2007). A handful of novel mechanisms have been described to account for the onset of immune dysfunctions in HIV disease both in vitro and in vivo (Che et al., 2010, 2012; Larsson et al., 2013; Vujkovic-Cvijin et al., 2013). Endogenous infections that alter the natural history of HIV disease are defined as cofactors of disease progression (Kumarasamy et al., 2005). Discussing the mechanisms produced by infectious cofactors with impact on the magnitude of disease pathology could shed light on how to design potential interventions that could decelerate disease progression. Hence, this minireview attempts to provide overall insight into the immunological events that could accelerate the development of each disease in the presence of co-infection, and also to describe the gaps in knowledge and the need for future research to develop preventive measures against HIV and tuberculosis.

How does HIV contribute to exacerbation of M. tuberculosis infection?

HIV-related dysfunction of local immune responses in HIV/TB co-infected individuals reduces the ability of granuloma, an organized structure comprising epithelioid macrophages surrounded by a rim of lymphocytes, to restrain tubercle bacilli, leading to their eventual multiplication and dissemination, thereby culminating in severe pathology (Lawn et al., 2002; Safi et al., 2003; de Noronha et al., 2008; Bezuidenhout et al., 2009). Furthermore, the exacerbation of tuberculosis pathology is linked to the increased replication of HIV at the sites of M. tuberculosis infection (Imperiali et al., 2001). HIV is known to replicate within activated CD4+ T cells and macrophages, which are known to accumulate at the site of granuloma (Imperiali et al., 2001). Elevated HIV-1 gag p24 levels and viral loads in bronchoalveolar lavage (BAL) fluid are detected in individuals with tuberculosis compared with individuals with no tuberculosis infection (Nakata et al., 1997). In addition, there is an increase in viral loads in pleural fluid compared with plasma among patients with pleural tuberculosis and greater HIV replication in activated macrophages co-infected with M. tuberculosis and HIV compared with HIV-infected macrophages, emphasizing that HIV replication is increased at sites of M. tuberculosis infection (Hoshino et al., 2002; Lawn et al., 2002).

The killing of CD4+ T cells by HIV within granuloma is associated with primary tuberculosis or reactivation of tuberculosis (Lawn et al., 2002; Diedrich & Flynn, 2011). Recent animal studies have demonstrated that monkeys co-infected with simian immunodeficiency virus strain mac251 (SIVmac251) and M. tuberculosis had fewer CD4+ T cells in granulomatous tissue than those with active tuberculosis alone (Diedrich et al., 2010). HIV-infected patients with lower CD4+ T-cell counts are more susceptible to tuberculosis than those with higher counts (Lawn et al., 2009; Diedrich et al., 2010). Furthermore, HIV/TB co-infected individuals have fewer CD4+ T cells in BAL fluid than those infected with tuberculosis alone (Kalsdorf et al., 2009).

The functionality of different immune cells such as macrophages and T cells are altered in co-infected individuals (Patel et al., 2007, 2009; Geldmacher et al., 2008, 2010; Kumawat et al., 2010). HIV/TB co-infected macrophages release lower levels of tumor necrosis factor-α (TNF-α) and induce less TNF-dependent apoptosis than those infected with M. tuberculosis alone (Patel et al., 2007, 2009; Kumawat et al., 2010) (Fig. 1). In addition, there is evidence for the negative impact of HIV on the ability of tuberculosis-specific T cells to contain bacterial establishment. For instance, there are fewer interferon-γ (IFN-γ)-producing M. tuberculosis-specific memory T cells following HIV infection in individuals with latent tuberculosis. Furthermore, studies have convincingly demonstrated lower IFN-γ and interleukin-2 (IL-2) production and proliferation by M. tuberculosis-specific T cells in HIV-infected individuals than in HIV-uninfected individuals with active tuberculosis (Hertoghe et al., 2000; Mendonça et al., 2007; Geldmacher et al., 2008). Recent findings showed that IL-10 production was significantly higher in HIV–TB co-infected individuals after M. tuberculosis stimulation, suggesting that chronic HIV infection could render the cell-mediated immunity (CMI) ineffective against M. tuberculosis (Geldmacher et al., 2010). Furthermore, there was less IL-2 production and higher macrophage inflammatory protein-1β (MIP-1β, also called CCL4) production by the M. tuberculosis-specific CD4+ T cells in HIV-infected vs. HIV-uninfected patients (Geldmacher et al., 2010), supporting the fact that HIV preferentially infects and depletes IL-2-producing CD4+ T cells and is partially inhibited from depleting MIP-1β-producing CD4+ T cells. In addition, Wax-D on the bacterial cell surface triggers IL-12 secretion by DCs and macrophages, facilitating the expansion of CD4+ Th1 cells, which in turn supports HIV establishment (Briken et al., 2004). HIV-1 also promotes the secretion of indoleamine 2,3 dioxygenase (IDO) a tryptophan-catabolizing enzyme required for T-cell suppression (Favre et al., 2010; Larsson et al., 2013; Planès & Bahraoui, 2013). A recent study has kindled interest in the role co-inhibitory molecules play in T-cell activation in HIV/TB co-infection. The study showed significantly higher expression of PD-1 on T cells from HIV–TB co-infected individuals than on T cells from tuberculosis patients and healthy controls (Jurado et al., 2012), further indicating that HIV could contribute to lessen CMI responses against tubercle bacilli (Fig. 1) by upregulating the expression of coinhibitory molecules on effector immune cells as described recently in a series of interesting in vitro (Shankar et al., 2011; Che et al., 2012; Larsson et al., 2013) and in vivo investigations (Velu et al., 2009). HIV infection could also induce expression of immune activation markers such as CD38, CD70, HLA-DR and CD45R0 to weaken T-cell responses against M. tuberculosis antigens (Flynn & Chan, 2001; Hazenberg et al., 2003) (Fig. 1).

Fig. 1

Proposed model of HIV/Mycobacterium tuberculosis co-infection: the ‘danger-couple’ model of disease pathogenesis. Mycobacterium tuberculosis and HIV have evolved to favor each other in facilitating disease pathogenesis. (a) Mycobacterium tuberculosis-infected resident alveolar macrophages produce increased levels of TNF-α, IL-1 and IL-6, leading to enhanced HIV replication (Kedzierska et al., 2003; Briken et al., 2004) and persistence within macrophages. Furthermore, HIV/M. tuberculosis-coinfected macrophages are less prone to undergo TNF-dependent apoptosis (Patel et al., 2007, 2009; Kumawat et al., 2010). (b) Mycobacterium tuberculosis increases the expression of CXCR4 in alveolar macrophages, favoring entry of only X4 viruses (Vanham et al., 1996; Wolday et al., 2005; Hoshino et al., 2004; Juffermans et al., 2001) potentially in chronic HIV infection. (c) Increased IDO levels and decreased tryptophan levels in primary tuberculosis has been shown to correlate with poor tuberculosis prognosis (Suzuki et al., 2012), and therefore the increased IFN-γ levels seen during primary tuberculosis and acute HIV infection might be associated with IDO-associated T-cell suppression, although prostaglandin E2 (PGE2) could upregulate IDO in DCs (von Bergwelt-Baildon et al., 2006). High expression of PD-1 in T cells of HIV/M. tuberculosis-coinfected individuals has also been shown (Jurado et al., 2012). In this context, M. tuberculosis could also foster anti-inflammatory attributes in DCs (Talaat et al., 2006), although the potential role of IDO in explaining this concept remains to be investigated. HIV infection induces expression of immune activation markers, CD38, CD70 and HLA-DR, weakening T-cell responses against M. tuberculosis antigens (Flynn & Chan, 2001; Hazenberg et al., 2003). Furthermore, high IL-10 and less IL-2 production in HIV/M. tuberculosis coinfection further explains the concept of diminished CMI responses against M. tuberculosis (Geldmacher et al., 2010). Mycobacterium tuberculosis Wax-D triggers IL-12 secretion by DCs and macrophages, facilitating the expansion of CD4+ Th1 cells, which in turn supports HIV persistence (not shown) (Briken et al., 2004). CXCR4, CX- chemokine receptor 4; DC, dendritic cell; IDO, indoleamine 2,3, dioxygenase; IFN-γ, interferon gamma; IL, interleukin; HLA-DR, human leukocyte antigen-DR; MФ, macrophage; MTB, Mycobacterium tuberculosis; PD-1, programmed death-1; Th1, thymus-derived helper T cell; TNF-α, tumor necrosis factor alpha.

Fig. 1

Proposed model of HIV/Mycobacterium tuberculosis co-infection: the ‘danger-couple’ model of disease pathogenesis. Mycobacterium tuberculosis and HIV have evolved to favor each other in facilitating disease pathogenesis. (a) Mycobacterium tuberculosis-infected resident alveolar macrophages produce increased levels of TNF-α, IL-1 and IL-6, leading to enhanced HIV replication (Kedzierska et al., 2003; Briken et al., 2004) and persistence within macrophages. Furthermore, HIV/M. tuberculosis-coinfected macrophages are less prone to undergo TNF-dependent apoptosis (Patel et al., 2007, 2009; Kumawat et al., 2010). (b) Mycobacterium tuberculosis increases the expression of CXCR4 in alveolar macrophages, favoring entry of only X4 viruses (Vanham et al., 1996; Wolday et al., 2005; Hoshino et al., 2004; Juffermans et al., 2001) potentially in chronic HIV infection. (c) Increased IDO levels and decreased tryptophan levels in primary tuberculosis has been shown to correlate with poor tuberculosis prognosis (Suzuki et al., 2012), and therefore the increased IFN-γ levels seen during primary tuberculosis and acute HIV infection might be associated with IDO-associated T-cell suppression, although prostaglandin E2 (PGE2) could upregulate IDO in DCs (von Bergwelt-Baildon et al., 2006). High expression of PD-1 in T cells of HIV/M. tuberculosis-coinfected individuals has also been shown (Jurado et al., 2012). In this context, M. tuberculosis could also foster anti-inflammatory attributes in DCs (Talaat et al., 2006), although the potential role of IDO in explaining this concept remains to be investigated. HIV infection induces expression of immune activation markers, CD38, CD70 and HLA-DR, weakening T-cell responses against M. tuberculosis antigens (Flynn & Chan, 2001; Hazenberg et al., 2003). Furthermore, high IL-10 and less IL-2 production in HIV/M. tuberculosis coinfection further explains the concept of diminished CMI responses against M. tuberculosis (Geldmacher et al., 2010). Mycobacterium tuberculosis Wax-D triggers IL-12 secretion by DCs and macrophages, facilitating the expansion of CD4+ Th1 cells, which in turn supports HIV persistence (not shown) (Briken et al., 2004). CXCR4, CX- chemokine receptor 4; DC, dendritic cell; IDO, indoleamine 2,3, dioxygenase; IFN-γ, interferon gamma; IL, interleukin; HLA-DR, human leukocyte antigen-DR; MФ, macrophage; MTB, Mycobacterium tuberculosis; PD-1, programmed death-1; Th1, thymus-derived helper T cell; TNF-α, tumor necrosis factor alpha.

How does tuberculosis exacerbate HIV-1 infection?

Co-infection with M. tuberculosis negatively impacts the HIV immune responses and this is demonstrated by a higher incidence of new AIDS-defining OIs in HIV/TB co-infected individuals (Pape et al., 1993). There appears to be high plasma viral load (PVL) (Goletti et al., 1996), and HIV replication is up-regulated in blood and pulmonary lymphocytes and alveolar macrophages ex vivo (Shattock et al., 1993; Zhang et al., 1995; Goletti et al., 1996; Lawn et al., 2011) in HIV-infected individuals with active tuberculosis disease. The exacerbated HIV replication in alveolar macrophages, the primary targets for M. tuberculosis, has also been detected in the BAL from co-infected patients (Lawn et al., 2011).

HIV uses co-receptor CCR5 predominantly during the establishment and early in the course of infection, whereas as the disease progresses the use of CXCR4 becomes more frequent (Rosas-Taraco et al., 2006). Mycobacterium tuberculosis creates an environment accommodating the replication of CXCR4-tropic HIV by increasing the expression of CXCR4 in alveolar macrophages and suppressing entry of CCR5-tropic HIV, thereby creating a selective pressure for CXCR4-tropic HIV (Vanham et al., 1996; Wolday et al., 2005; Hoshino et al., 2004; Juffermans et al., 2001).

It has been established that HIV and M. tuberculosis infections in concert stimulate TNF-α production, which in turn has been shown to enhance HIV replication in macrophages (Kedzierska et al., 2003). Mycobacterium tuberculosis infection activates the suppressor of cytokine signaling 1 (SOCS1), an inducible host factor during HIV-1 infection that facilitates viral replication by inhibiting type-1 IFN antiviral signaling (Fenner et al., 2006). Apart from the effects on HIV replication, M. tuberculosis infection has also been shown to down-regulate the proinflammatory and antigen-presenting abilities, and activate the anti-inflammatory functions of DCs (Talaat et al., 2006). DC-mediated activation of T cells is reportedly impaired in HIV infection, and migration of DCs along with HIV contributes to efficient viral dissemination (Wang et al., 2009; Geldmacher et al., 2008; Geijtenbeek et al., 2000). Wax-D has also been implicated in the activation of HIV replication by enhancing TNF-α and IL-6 production by DCs (Briken et al., 2004), which could give rise to increased HIV-1 replication furthering immunosuppression. Here, we have proposed a ‘danger-couple’ model of HIV/M. tuberculosis co-infection (Fig. 1), whereby HIV-infected T cells become dysfunctional, eventually leading to the loss of intracellular killing abilities of macrophages harboring M. tuberculosis. Simultaneously, the M. tuberculosis-infected macrophages containing LAM (Wax-D) produce increased levels of TNF-α, IL-1 and IL-6, leading to enhanced viral replication (Briken et al., 2004) and HIV persistence within macrophages. One recent theory is that HIV helps M. tuberculosis persist within the macrophages, facilitating increased synthesis of IFN-γ, which promotes secretion of IDO, a tryptophan-catabolizing enzyme, leading to T-cell inhibition, but this remains to be investigated. If IFN-γ levels have no association with IDO secretion by DCs, the role of prostaglandin E2 (PGE2) could be considered (von Bergwelt-Baildon et al., 2006) for potential investigation. By decreasing available tryptophan and producing tryptophan metabolites, such as kynurenine (Kyn), IDO inhibits T-cell functions and leads to immune suppression. Beguilingly, one recent study points to increased IDO levels and decreased tryptophan levels in primary tuberculosis and correlated the levels with poor tuberculosis prognosis (Suzuki et al., 2012) (Fig. 1).

Reciprocal effects of HIV/M. tuberculosis on each other

Several in vitro studies have demonstrated that phagocytosis of M. tuberculosis induces macrophage activation, and production of proinflammatory cytokines, namely TNF-α, IL-1β and IL-6 by macrophages, is known to enhance replication of HIV-1 (Molina et al., 1989; Weiss et al., 1989; Birx et al., 1990; Emilie et al., 1990; Lafeuillade et al., 1991; Herbein & Varin, 2010; Cozzi-Lepri et al., 2011). Growth of M. tuberculosis was observed to be significantly greater in HIV-1-infected monocyte-derived macrophages (MDMs) compared with that in HIV-1-negative cells (Imperiali et al., 2001). Also, adding TNF-α to HIV-1-infected MDMs induced a significant increase of M. tuberculosis growth, compared with cultures performed in the absence of the cytokine, whereas addition of TNF-α had no effect on M. tuberculosis growth in uninfected MDMs (Imperiali et al., 2001). In latently HIV-1-infected promonocytic cells, phagocytosis of M. tuberculosis induced viral production, and in acutely HIV-1-infected MDMs, M. tuberculosis growth was increased (Imperiali et al., 2001). Furthermore, HIV-1 infection induced a greater bacilli burden in co-infected cell cultures and specifically induced accelerated growth of M. tuberculosis; in turn, the bacteria induced the replication of HIV-1 (Pathak et al., 2010). The co-infection of HIV-1/TB synergistically decreased the viability of macrophages and increased levels of proinflammatory cytokines and this seemed to be specific to M. tuberculosis rather than other species of mycobacteria (Pathak et al., 2010).

Dual complications: clinical presentation and diagnosis of tuberculosis in HIV/M. tuberculosis co-infection

The clinical presentation of tuberculosis in HIV/M. tuberculosis-coinfected individuals is known to vary according to the immune status, and atypical features usually observed include lower lobe involvement with a trend towards diffuse infection rather than cavitation (Aaron et al., 2004). In severely immunocompromised HIV-infected individuals, pulmonary basal involvement, hilar or mediastinal lymphadenopathies, and miliary tuberculosis are most commonly observed (Perlman et al., 1997). Diagnosis of active tuberculosis in HIV-infected individuals is challenging, because there are fewer tuberculosis bacilli in sputum specimens from individuals with HIV/TB co-infection than from HIV-uninfected patients with pulmonary tuberculosis due to markedly reduced transfer of bacilli in respiratory secretions (Mugusi et al., 2006; Padmapriyadarsini et al., 2011).

Extrapulmonary tuberculosis in HIV-positive individuals

The proportion of extrapulmonary tuberculosis (EPTB) has been reported to be higher among HIV-infected individuals than among the immunocompetent population (Sharma et al., 2005; Patel et al., 2011). EPTB is high significant in HIV being designated an AIDS-defining illness and occurs frequently and earlier than most other OIs and with high rates of mortality (Shanmuganathan et al., 2013). Several studies have demonstrated lymph nodes as the most common site of EPTB infection among HIV-infected individuals (Deivanayagam et al., 2001; Leeds et al., 2012; Shanmuganathan et al., 2013). According to a recent study, EPTB is the most common form of tuberculosis in HIV patients with low CD4+ T-cell counts, and the common presenting symptoms of EPTB include fever, weight loss and cough (Spalgais et al., 2013).

Tuberculosis and immune restitution inflammatory syndrome

Immune reconstitution inflammatory syndrome (IRIS) is an adverse consequence of the restoration of pathogen-specific immune responses in HIV-infected patients during the initial period of highly active antiretroviral treatment (HAART) (Kumarasamy et al., 2004). Although IRIS is associated with certain infectious and non-infectious conditions (Shankar et al., 2007), the morbidity associated with HIV/TB co-infection is significantly higher than for the other conditions. HIV-infected patients with low CD4+ T-cell counts ‘immunologically’ tolerate the presence of the tubercle bacilli as the host is unable to mount an inflammatory response (Shankar et al., 2008a, b). Tuberculosis-associated IRIS is considered critical in developing countries, where the proportion of HIV/TB IRIS is reportedly high, ranging from 10% to 43% (Breton et al., 2004; Shelburne et al., 2005; Murdoch et al., 2008; Haddow et al., 2012). Although the pathophysiology of IRIS is incompletely understood, sustained Th1 responses evident by increased IFN-γ responses against the mycobacterial antigens, followed by dysregulation of cytokine secretion and T-cell migration to the inflammatory site have been demonstrated (Bourgarit et al., 2006; Vignesh et al., 2013).

A recent study demonstrated the possible role of Th1 responses in the pathogenesis of TB-IRIS and showed that HIV-infected patients who develop TB-IRIS had higher Th1 responses to M. tuberculosis antigens before they began HAART, and that these responses are amplified after initiation of HAART (Vignesh et al., 2013). This mechanism could possibly be due to the higher mycobacterial load in patients who develop TB-IRIS, leading to a larger number of Th1 cells and also there might be acquired susceptibility to produce higher Th1 responses. This acquired susceptibility could be related to perturbations of innate immune responses that have been associated with TB-IRIS, such as elevated production of IL-18, a potent stimulator of Th1 responses, and CXCL10, a well-known chemoattractant for Th1 cells (Vignesh et al., 2013). This study also investigated the expression of CCR5 and CXCR3 expression on T cells and found an increased proportion of CCR5+ CD4+ T cells among patients with TB-IRIS (Vignesh et al., 2013). Elevated pre-HAART levels of TNF, high inflammation biomarker levels and significantly lower levels of antibodies to phenolic glycolipid (PGL-TB1) antigen existed in individuals who developed TB-IRIS than those who did not (Simonney et al., 2008; Boulware et al., 2011). A recent study indicated natural killer (NK) cell degranulation levels as a predictor for TB-IRIS among HIV/TB co-infected patients initiating HAART (Pean et al., 2012).

Management of HIV/TB co-infection – therapeutic considerations

The treatment modality for tuberculosis in HIV-infected individuals is the same as for HIV-uninfected, with the regimen of a four-drug intensive phase of 2 months, followed by 4 months of a two-drug regimen in continuation phase (Treatment of tuberculosis: Guidelines, WHO, 2010). Development of multi-drug resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is a challenge faced by healthcare providers when treating tuberculosis, especially in TB/HIV co-infected individuals. Two mechanisms have been suggested that link drug-resistant tuberculosis to HIV infection. One is tuberculosis drug malabsorption, especially with rifampin and ethambutol leading to treatment failure, the other being that drug-resistant strains might be less virulent and preferentially aid disease progression in HIV patients with a compromised immune system, as opposed to immune-competent individuals (Patel et al., 1995; Suchindran et al., 2009).

The antiretroviral drug regimen should be chosen on the basis of minimal drug interactions with the anti-tuberculosis treatment (Londhey, 2009). Rifampicin is known to interact with non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) (Varghese et al., 2013). Drug–drug interactions between rifampicin and NNRTIs leads to subtherapeutic levels of NNRTIs and subsequent treatment failure. Nevirapine is not recommended for individuals receiving rifampicin treatment for TB, where it reportedly decreases the serum concentration of nevirapine by about 50% (Ribera et al., 2001). Efavirenz is the drug of choice by reason of manageable drug–drug interactions, except in conditions such as pregnancy where it is contraindicated (Narita et al., 2000). To prevent drug–drug interactions while starting treatment with PIs with rifabutin, an alternative drug is recommended as it does not affect the serum concentrations of PIs (Sundaram et al., 2008). In HIV-infected individuals with tuberculosis, antiretroviral treatment (ART) should be initiated during tuberculosis treatment regardless of CD4+ T-cell counts. Recent studies have clearly shown that initiation of ART 2 weeks after tuberculosis treatment is more beneficial than delaying ART for 8 weeks. Despite the increased incidence of TB-IRIS, this was shown to reduce mortality (Abdool Karim et al., 2010; Blanc et al., 2011; Havlir et al., 2011). However, these data are based on studies from countries with a high tuberculosis burden with limited resources and further data from large-scale multisite trials are warranted.

Conclusions

Conventionally, coinfections in HIV-infected individuals accelerate the disease progression (Shankar et al., 2008a, b). HIV/TB coinfection continues to be a dual threat to healthcare providers and represents a novel pathogenic scenario globally. Countries with limited resources are most affected with a high burden of both diseases, yet have strained healthcare budgets. The most logical and practical option to combat the coinfections would be to develop an effective combined vaccine for both HIV/TB, although currently no effective vaccine exist for either HIV or tuberculosis. Research priorities that need to be urgently addressed include further understanding of the immunopathogenic mechanisms underlying the mutual exacerbations of tuberculosis and HIV disease to combat them effectively and optimizing the treatment modalities to minimize complications such as TB-IRIS and drug–drug interactions. The following scientific objectives are needed for effective integration of knowledge on the HIV/TB coinfection: developing standard in vitro and in vivo models for studying the mechanisms of coinfection, employing mathematical and computer-based simulation models to understand the immune responses better and regulation of T-cell differentiation during coinfection. Moreover, an integrated approach to the two infections, based on drafting effective policies to contain both, is essential.

Acknowledgements

The authors acknowledge funding support provided for this work by the University of Malaya Research Grant (UMRG) of the Health and Translational Medicine Research Cluster, University of Malaya, Kuala Lumpur, to E.M.S. (RG448-12HTM) and UM.C/625/1/HIR/MoHE/MED/014 to A.K. by High Impact Research (HIR), University of Malaya, and for M.L. AI52731, the Swedish Research Council, the Swedish Physicians Against AIDS Research Foundation, the Swedish International Development Cooperation Agency, SIDA SARC, VINNMER for Vinnova, Linköping University Hospital Research Fund, CALF and the Swedish Society of Medicine.

References

Aaron
L
Saadoun
D
Calatroni
I
et al
. (
2004
)
Tuberculosis in HIV-infected patients: a comprehensive review
.
Clin Microbiol Infect
 
10
:
388
398
.
Abdool Karim
SS
Naidoo
K
Grobler
A
et al
. (
2010
)
Timing of initiation of antiretroviral drugs during tuberculosis therapy
.
N Engl J Med
 
362
:
697
706
.
Bezuidenhout
J
Roberts
T
Muller
L
van Helden
P
Walzl
G
(
2009
)
Pleural tuberculosis in patients with early HIV infection is associated with increased TNF-α expression and necrosis in granulomas
.
PLoS One
 
4
:
e4228
.
Birx
DL
Redfield
RR
Tencer
K
Fowler
A
Burke
DS
Tosato
G
(
1990
)
Induction of interleukin-6 during human immunodeficiency virus infection
.
Blood
 
76
:
2303
2310
.
Blanc
F-X
Sok
T
Laureillard
D
et al
. (
2011
)
Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis
.
N Engl J Med
 
365
:
1471
1481
.
Boulware
DR
Hullsiek
KH
Puronen
CE
et al
. (
2011
)
Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death
.
J Infect Dis
 
203
:
1637
1646
.
Bourgarit
A
Carcelain
G
Martinez
V
Lascoux
C
Delcey
V
Gicquel
B
Vicaut
E
Lagrange
PH
Sereni
D
Autran
B
(
2006
)
Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients
.
AIDS
 
20
:
F1
F7
.
Breton
G
Duval
X
Estellat
C
Poaletti
X
Bonnet
D
Mvondo Mvondo
D
Longuet
P
Leport
C
Vildé
JL
(
2004
)
Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy
.
Clin Infect Dis
 
39
:
1709
1712
.
Briken
V
Porcelli
SA
Besra
GS
Kremer
L
(
2004
)
Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response
.
Mol Microbiol
 
53
:
391
403
.
Che
KF
Sabado
RL
Shankar
EM
Tjomsland
V
Messmer
D
Bhardwaj
N
Lifson
JD
Larsson
M
(
2010
)
HIV-1 impairs in vitro priming of naïve T cells and gives rise to contact-dependent suppressor T cells
.
Eur J Immunol
 
40
:
2248
2258
.
Che
KF
Shankar
EM
Muthu
S
Zandi
S
Sigvardsson
M
Hinkula
J
Messmer
D
Larsson
M
(
2012
)
p38 Mitogen-activated protein kinase/signal transducer and activator of transcription-3 pathway signaling regulates expression of inhibitory molecules in T cells activated by HIV-1-exposed dendritic cells
.
Mol Med
 
18
:
1169
1182
.
Coughlin
MM
Bellini
WJ
Rota
PA
(
2013
)
Contribution of dendritic cells to measles virus induced immunosuppression
.
Rev Med Virol
 
23
:
126
138
.
Cozzi-Lepri
A
French
MA
Baxter
J
Okhuysen
P
Plana
M
Neuhaus
J
Landay
A
INSIGHT SMART study group
(
2011
)
Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial
.
AIDS
 
25
:
1207
1217
.
de Noronha
ALL
Báfica
A
Nogueira
L
Barral
A
Barral-Netto
M
(
2008
)
Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production
.
Pathol Res Pract
 
204
:
155
161
.
Deivanayagam
CN
Rajasekaran
S
Senthilnathan
V
Krishnarajsekhar
R
Raja
K
Chandrasekar
C
Palanisamy
S
Dinesh
AS
Jothivel
G
Elango
SV
(
2001
)
Clinico-radiological spectrum of tuberculosis among HIV seropositives: a Tambaram study
.
Indian J Tuberc
 
48
:
123
.
Dhiman
R
Indramohan
M
Barnes
PF
Nayak
RC
Paidipally
P
Rao
LV
Vankayalapati
R
(
2009
)
IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion
.
J Immunol
 
183
:
6639
6645
.
Diedrich
CR
Flynn
JL
(
2011
)
HIV-1/Mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis?
Infect Immun
 
79
:
1407
1417
.
Diedrich
CR
Mattila
JT
Klein
E
Janssen
C
Phuah
J
Sturgeon
TJ
Montelaro
RC
Lin
PL
Flynn
JL
(
2010
)
Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load
.
PLoS One
 
5
:
e9611
.
Dinleyici
EC
Kurugol
Z
Turel
O
et al
. (
2012
)
The epidemiology and economic impact of varicella-related hospitalizations in Turkey from 2008 to 2010: a nationwide survey during the pre-vaccine era (VARICOMP study)
.
Eur J Pediatr
 
171
:
817
825
.
Emilie
D
Peuchmaur
M
Maillot
MC
Crevon
MC
Brousse
N
Delfraissy
JF
Dormont
J
Galanaud
P
(
1990
)
Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes
.
J Clin Invest
 
86
:
148
159
.
Favre
D
Mold
J
Hunt
PW
(
2010
)
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease
.
Sci Transl Med
 
2
:
32
36
.
Flynn
JL
Chan
J
(
2001
)
Immunology of tuberculosis
.
Annu Rev Immunol
 
19
:
93
129
.
Forrellad
MA
Klepp
LI
Gioffré
A
Sabio y García
J
Morbidoni
HR
de la Paz Santangelo
M
Cataldi
AA
Bigi
F
(
2013
)
Virulence factors of the Mycobacterium tuberculosis complex
.
Virulence
 
4
:
3
66
.
Geijtenbeek
TB
Kwon
DS
Torensma
R
(
2000
)
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
.
Cell
 
100
:
587
597
.
Geldmacher
C
Schuetz
A
Ngwenyama
N
(
2008
)
Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection
.
J Infect Dis
 
198
:
1590
1598
.
Geldmacher
C
Ngwenyama
N
Schuetz
A
(
2010
)
Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection
.
J Exp Med
 
207
:
2869
2881
.
Goletti
D
Weissman
D
Jackson
RW
Graham
NM
Vlahov
D
Klein
RS
Munsiff
SS
Ortona
L
Cauda
R
Fauci
AS
(
1996
)
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation
.
J Immunol
 
157
:
1271
1278
.
Haddow
LJ
Moosa
MY
Mosam
A
Moodley
P
Parboosing
R
Easterbrook
PJ
(
2012
)
Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa
.
PLoS One
 
7
:
e40623
.
Havlir
DV
Kendall
MA
Ive
P
et al
. (
2011
)
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
.
N Engl J Med
 
365
:
1482
1491
.
Hazenberg
MD
Otto
SA
van Benthem
BH
Roos
MT
Coutinho
RA
Lange
JM
Hamann
D
Prins
M
Miedema
F
(
2003
)
Persistent immune activation in HIV-1 infection is associated with progression to AIDS
.
AIDS
 
17
:
1881
1888
.
Herbein
G
Varin
A
(
2010
)
The macrophage in HIV-1 infection: from activation to deactivation?
Retrovirology
 
7
:
33
.
Hertoghe
T
Wajja
A
Ntambi
L
et al
. (
2000
)
T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB)
.
Clin Exp Immunol
 
122
:
350
357
.
Hoshino
Y
Nakata
K
Hoshino
S
Honda
Y
Tse
DB
Shioda
T
Rom
WN
Weiden
M
(
2002
)
Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines
.
J Exp Med
 
195
:
495
505
.
Hoshino
Y
Tse
DB
Rochford
G
et al
. (
2004
)
Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human macrophages
.
J Immunol
 
172
:
6251
6258
.
Imperiali
FG
Zaninoni
A
La Maestra
L
Tarsia
P
Blasi
F
Barcellini
W
(
2001
)
Increased Mycobacterium tuberculosis growth in HIV-1-infected human macrophages: role of tumor necrosis factor-alpha
.
Clin Exp Immunol
 
123
:
435
442
.
Juffermans
NP
Speelman
P
Verbon
A
Veenstra
J
Jie
C
van Deventer
SJ
van Der Poll
T
(
2001
)
Patients with active tuberculosis have increased expression of HIV coreceptors CXCR4 and CCR5 on CD4+ T cells
.
Clin Infect Dis
 
32
:
650
652
.
Jurado
JO
Pasquinelli
V
Alvarez
IB
, (
2012
)
ICOS, SLAM and PD-1 expression and regulation on T lymphocytes reflect the immune dysregulation in patients with HIV-related illness with pulmonary tuberculosis
.
J Int AIDS Soc
 
15
:
17428
.
Kalsdorf
B
Scriba
TJ
Wood
K
Day
CL
Dheda
K
Dawson
R
Hanekom
WA
Lange
C
Wilkinson
RJ
(
2009
)
HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria
.
Am J Respir Crit Care Med
 
180
:
1262
1270
.
Kedzierska
K
Crowe
SM
Turville
S
Cunningham
AL
(
2003
)
The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages
.
Rev Med Virol
 
13
:
39
56
.
Kownhar
H
Shankar
EM
Rajan
R
Vengatesan
A
Rao
UA
(
2007
)
Prevalence of Campylobacter jejuni and enteric bacterial pathogens among hospitalized HIV infected versus non-HIV infected patients with diarrhoea in southern India
.
Scand J Infect Dis
 
39
:
862
866
.
Kumarasamy
N
Chaguturu
S
Mayer
KH
Solomon
S
Yepthomi
HT
Balakrishnan
P
Flanigan
TP
(
2004
)
Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India
.
J Acquir Immune Defic Syndr
 
37
:
1574
1576
.
Kumarasamy
N
Vallabhaneni
S
Flanigan
TP
Mayer
KH
Solomon
S
(
2005
)
Clinical profile of HIV in India
.
Indian J Med Res
 
121
:
377
394
.
Kumawat
K
Pathak
SK
Spetz
A-L
Kundu
M
Basu
J
(
2010
)
Exogenous Nef is an inhibitor of Mycobacterium tuberculosis-induced tumor necrosis factor-alpha production and macrophage apoptosis
.
J Biol Chem
 
285
:
12629
12637
.
Lafeuillade
A
Poizot-Martin
I
Quilichini
R
Gastaut
JA
Kaplanski
S
Farnarier
C
Mege
JL
Bongrand
P
(
1991
)
Increased interleukin-6 production is associated with disease progression in HIV infection
.
AIDS
 
5
:
1139
1140
.
Larsson
M
Shankar
EM
Che
KF
Saeidi
A
Ellegård
R
Barathan
M
Velu
V
Kamarulzaman
A
(
2013
)
Molecular signatures of T-cell inhibition in HIV-1 infection
.
Retrovirology
 
10
:
31
.
Lawn
SD
Butera
ST
Shinnick
TM
(
2002
)
Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis
.
Microbes Infect
 
4
:
635
646
.
Lawn
SD
Myer
L
Edwards
D
Bekker
L-G
Wood
R
(
2009
)
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa
.
AIDS
 
23
:
1717
1725
.
Lawn
SD
Brooks
SV
Kranzer
K
Nicol
MP
Whitelaw
A
Vogt
M
Bekker
LG
Wood
R
(
2011
)
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study
.
PLoS Med
 
8
:
e1001067
.
Leeds
IL
Magee
MJ
Kurbatova
EV
del Rio
C
Blumberg
HM
Leonard
MK
Kraft
CS
(
2012
)
Site of EPTB is associated with HIV infection
.
Clin Infect Dis
 
55
:
75
81
.
Londhey
VA
(
2009
)
HIV and tuberculosis – “a cursed duo” in the HAART era
.
J Assoc Physicians India
 
57
:
1
2
.
Mansell
A
Smith
R
Doyle
SL
Gray
P
Fenner
JE
Crack
PJ
Nicholson
SE
Hilton
DJ
O'Neill
LA
Hertzog
PJ
(
2006
)
Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity
.
Nat Immunol
 
7
:
33
39
.
Mendonça
M
Tanji
MM
Silva
LC
Silveira
GG
Oliveira
SC
Duarte
AJ
Benard
G
(
2007
)
Deficient in vitro anti-mycobacterial immunity despite successful long-term highly active antiretroviral therapy in HIV-infected patients with past history of tuberculosis infection or disease
.
Clin Immunol
 
125
:
60
66
.
Molina
JM
Scadden
DT
Byrn
R
Dinarello
CA
Groopman
JE
(
1989
)
Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus
.
J Clin Invest
 
84
:
733
737
.
Mugusi
F
Villamor
E
Urassa
W
Saathoff
E
Bosch
RJ
Fawzi
WW
(
2006
)
HIV co-infection, CD4 cell counts and clinical correlates of bacillary density in pulmonary tuberculosis
.
Int J Tuberc Lung Dis
 
10
:
663
669
.
Murdoch
DM
Venter
WDF
Feldman
C
Van Rie
A
(
2008
)
Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study
.
AIDS
 
22
:
601
610
.
Muthu
SE
Aberna
RA
Mohan
V
Premalatha
G
Srinivasan
RS
Thyagarajan
SP
Rao
UA
(
2006
)
Phenotypes of isolates of Pseudomonas aeruginosa in a diabetes care center
.
Arch Med Res
 
37
:
95
101
.
Nakata
K
Rom
WN
Honda
Y
Condos
R
Kanegasaki
S
Cao
Y
Weiden
M
(
1997
)
Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung
.
Am J Respir Crit Care Med
 
155
:
996
1003
.
Narita
M
Stambaugh
JJ
Hollender
ES
Jones
D
Pitchenik
AE
Ashkin
D
(
2000
)
Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis
.
Clin Infect Dis
 
30
:
779
783
.
Padmapriyadarsini
C
Narendran
G
Swaminathan
S
(
2011
)
Diagnosis & treatment of tuberculosis in HIV co-infected patients
.
Indian J Med Res
 
134
:
850
865
.
Pape
JW
Jean
SS
Ho
JL
Hafner
A
Johnson
WD
Jr
(
1993
)
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
.
Lancet
 
342
:
268
272
.
Patel
KB
Belmonte
R
Crowe
HM
(
1995
)
Drug malabsorption and resistant tuberculosis in HIV-infected patients
.
N Engl J Med
 
332
:
336
337
.
Patel
NR
Zhu
J
Tachado
SD
Zhang
J
Wan
Z
Saukkonen
J
Koziel
H
(
2007
)
HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis
.
J Immunol
 
179
:
6973
6980
.
Patel
NR
Swan
K
Li
X
Tachado
SD
Koziel
H
(
2009
)
Impaired M. tuberculosis-mediated apoptosis in alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3
.
J Leukoc Biol
 
86
:
53
60
.
Patel
AK
Thakrar
SJ
Ghanchi
FD
(
2011
)
Clinical and laboratory profile of patients with TB/HIV coinfection: a case series of 50 patients
.
Lung India
 
28
:
93
96
.
Pathak
S
Wentzel-Larsen
T
Asjö
B
(
2010
)
Effects of in vitro HIV-1 infection on mycobacterial growth in peripheral blood monocyte-derived macrophages
.
Infect Immun
 
78
:
4022
4032
.
Pawlowski
A
Jansson
M
Sköld
M
Rottenberg
ME
Källenius
G
(
2012
)
Tuberculosis and HIV co-infection
.
PLoS Pathog
 
8
:
e1002464
.
Pean
P
Nerrienet
E
Madec
Y
(
2012
)
Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis
.
Blood
 
119
:
3315
3320
.
Perlman
DC
el-Sadr
WM
Nelson
ET
Matts
JP
Telzak
EE
Salomon
N
Chirgwin
K
Hafner
R
(
1997
)
Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression
.
Clin Infect Dis
 
25
:
242
246
.
Planès
R
Bahraoui
E
(
2013
)
HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation
.
PLoS One
 
8
:
e74551
.
Ray
S
Talukdar
A
Kundu
S
Khanra
D
Sonthalia
N
(
2013
)
Diagnosis and management of miliary tuberculosis: current state and future perspectives
.
Ther Clin Risk Manag
 
9
:
9
26
.
Ribera
E
Pou
L
Lopez
RM
Crespo
M
Falco
V
Ocaña
I
Ruiz
I
Pahissa
A
(
2001
)
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis
.
J Acquir Immune Defic Syndr
 
28
:
450
453
.
Rosas-Taraco
AG
Arce-Mendoza
AY
Caballero-Olín
G
Salinas-Carmona
MC
(
2006
)
Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection
.
AIDS Res Hum Retroviruses
 
22
:
45
51
.
Safi
H
Gormus
BJ
Didier
PJ
Blanchard
JL
Lakey
DL
Martin
LN
Murphey-Corb
M
Vankayalapati
R
Barnes
PF
(
2003
)
Spectrum of manifestations of Mycobacterium tuberculosis infection in primates infected with SIV
.
AIDS Res Hum Retroviruses
 
19
:
585
595
.
Shankar
EM
Rajasekaran
S
Rao
UA
Paramesh
P
Krishnakumar
R
Rajan
R
Kownhar
H
(
2005
)
Colonization of mycoplasma in the upper respiratory tract of AIDS patients with pulmonary symptoms in Chennai, India
.
Indian J Med Res
 
122
:
506
510
.
Shankar
EM
Kumarasamy
N
Bella
D
Renuka
S
Kownhar
H
Suniti
S
Rajan
R
Rao
UA
(
2006a
)
Pneumonia and pleural effusion due to Cryptococcus laurentii in a clinically proven case of AIDS
.
Can Respir J
 
13
:
275
278
.
Shankar
EM
Kumarasamy
N
Rajan
R
Balakrishnan
P
Solomon
S
Devaleenol
B
Rao
UA
(
2006b
)
Aspergillus fumigatus, Pneumocystis jiroveci, Klebsiella pneumoniae & Mycoplasma fermentans co-infection in a HIV infected patient with respiratory conditions from southern India
.
Indian J Med Res
 
123
:
181
184
.
Shankar
EM
Vignesh
R
Murugavel
KG
Balakrishnan
P
Sekar
R
Lloyd
CA
Solomon
S
Kumarasamy
N
(
2007
)
Immune reconstitution inflammatory syndrome in association with HIV/AIDS and tuberculosis: views over hidden possibilities
.
AIDS Res Ther
 
4
:
29
.
Shankar
EM
Solomon
SS
Vignesh
R
Murugavel
KG
Sundaram
M
Solomon
S
Balakrishnan
P
Kumarasamy
N
(
2008a
)
GB virus infection: a silent anti-HIV panaceae within?
Trans R Soc Trop Med Hyg
 
102
:
1176
1180
.
Shankar
EM
Vignesh
R
Velu
V
Murugavel
KG
Sekar
R
Balakrishnan
P
Lloyd
CA
Saravanan
S
Solomon
S
Kumarasamy
N
(
2008b
)
Does CD4+ CD25+ Foxp3+ cell (Treg) and IL-10 profile determine susceptibility to immune reconstitution inflammatory syndrome (IRIS) in HIV disease?
J Inflamm
 
18
:
2
.
Shankar
EM
Che
KF
Messmer
D
Lifson
JD
Larsson
M
(
2011
)
Expression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells
.
Mol Med
 
17
:
229
240
.
Shanmuganathan
A
Srinivasan
R
Thilagavathy
G
Sathishkumar
D
Sidduraj
C
James
B
(
2013
)
Determination of sites involved, HIV co–infection and utility of diagnostic modalities in EPTB
.
J Clin Diagn Res
 
7
:
1644
1646
.
Sharma
SK
Mohan
A
Kadhiravan
T
(
2005
)
HIV–TB co-infection; epidemiology, diagnosis and management
.
Indian J Med Res
 
121
:
550
567
.
Shattock
RJ
Friedland
JS
Griffin
GE
(
1993
)
Modulation of HIV transcription in and release from human monocytic cells following phagocytosis of Mycobacterium tuberculosis
.
Res Virol
 
144
:
7
12
.
Shelburne
SA
Visnegarwala
F
Darcourt
J
Graviss
EA
Giordano
TP
White
AC
Jr
Hamill
RJ
(
2005
)
Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy
.
AIDS
 
19
:
399
406
.
Simonney
N
Dewulf
G
Herrmann
J-L
et al
. (
2008
)
Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV–TB patients
.
Tuberculosis
 
88
:
453
461
.
Spalgais
S
Jaiswal
A
Puri
M
Sarin
R
Agarwal
U
(
2013
)
Clinical profile and diagnosis of extrapulmonary TB in HIV infected patients: routine abdominal ultrasonography increases detection of abdominal ultrasonography increases detection of abdominal tuberculosis
.
Indian J Tuberc
 
60
:
147
153
.
Suchindran
S
Brouwer
ES
Van Rie
A
(
2009
)
Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review
PLoS One
 
4
:
e5561
.
Sundaram
M
Saghayam
S
Priya
B
Venkatesh
KK
Balakrishnan
P
Shankar
EM
Murugavel
KG
Solomon
S
Kumarasamy
N
(
2008
)
Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India
.
Int J Infect Dis
 
12
:
e61
e66
.
Suzuki
Y
Suda
T
Asada
K
et al
. (
2012
)
Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis
.
Clin Vaccine Immunol
 
19
:
436
442
.
Talaat
KR
Bonawitz
RE
Domenech
P
Nutman
TB
(
2006
)
Preexposure to live Brugia malayi microfilariae alters the innate response of human dendritic cells to Mycobacterium tuberculosis
.
J Infect Dis
 
193
:
196
204
.
Tan
CH
Kontoyiannis
DP
Viswanathan
C
Iyer
RB
(
2010
)
Tuberculosis: a benign impostor
.
Am J Roentgenol
 
194
:
555
561
.
UNAIDS
(
2012
)
World AIDS Day Report
 .
UNAIDS
,
Geneva
.
Vandal
OH
Nathan
CF
Ehrt
S
(
2009
)
Acid resistance in Mycobacterium tuberculosis
.
J Bacteriol
 
191
:
4714
4721
.
Vanham
G
Edmonds
K
Qing
L
et al
. (
1996
)
Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection
.
Clin Exp Immunol
 
103
:
30
34
.
Varghese
GM
Janardhanan
J
Ralph
R
Abraham
OC
(
2013
)
The twin epidemics of tuberculosis and HIV
.
Curr Infect Dis Rep
 
15
:
77
84
.
Velu
V
Titanji
K
Zhu
B
et al
. (
2009
)
Enhancing SIV-specific immunity in vivo by PD-1 blockade
.
Nature
 
458
:
206
210
.
Vignesh
R
Balakrishnan
P
Shankar
EM
Murugavel
KG
Hanas
S
Cecelia
AJ
Thyagarajan
SP
Solomon
S
Kumarasamy
N
(
2007
)
High proportion of isosporiasis among HIV-infected patients with diarrhea in southern India
.
Am J Trop Med Hyg
 
77
:
823
824
.
Vignesh
R
Shankar
EM
Balakrishnan
P
Murugavel
KG
Paul
PI
Sekar
R
Solomon
S
Kumarasamy
N
(
2008
)
Isospora belli, Strongyloides stercoralis and hookworm multiple-infection in a person with HIV infection and normal CD4+ T-lymphocyte count
.
Indian J Med Res
 
127
:
403
405
.
Vignesh
R
Kumarasamy
N
Lim
A
et al
. (
2013
)
TB-IRIS after initiation of anti-retroviral therapy is associated with expansion of pre-existent Th1 responses against Mycobacterium tuberculosis antigens
.
J Acquir Immune Defic Syndr
 
64
:
241
248
.
von Bergwelt-Baildon
MS
Popov
A
Saric
T
et al
. (
2006
)
CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition
.
Blood
 
108
:
228
237
.
Vujkovic-Cvijin
I
Dunham
RM
Iwai
S
et al
. (
2013
)
Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism
.
Sci Transl Med
 
5
:
193ra91
.
Wang
JH
Kwas
C
Wu
L
(
2009
)
Intercellular adhesion molecule 1 (ICAM-1), but not ICAM-2 and -3, is important for dendritic cell-mediated human immunodeficiency virus type 1 transmission
.
J Virol
 
83
:
4195
4204
.
Weiss
L
Haeffner-Cavaillon
N
Laude
M
Gilquin
J
Kazatchkine
MD
(
1989
)
HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1 alpha in vitro
.
AIDS
 
3
:
695
699
.
WHO
(
2008
)
Global Tuberculosis Control–Surveillance, Planning, Financing. WHO Report WHO/HTM/TB/2008393
 .
World Health Organization
,
Geneva
.
WHO
(
2010
)
Treatment of Tuberculosis: Guidelines
 .
World Health Organization
,
Geneva
.
WHO
(
2011
)
Tuberculosis Fact Sheet
 .
World Health Organization
,
Geneva
.
Wolday
D
Tegbaru
B
Kassu
A
Messele
T
Coutinho
R
van Baarle
D
Miedema
F
(
2005
)
Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients
.
J Acquir Immune Defic Syndr
 
39
:
265
271
.
Zhang
Y
Nakata
K
Weiden
M
Rom
WN
(
1995
)
Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat
.
J Clin Invest
 
95
:
2324
2331
.
An interesting perspective from a multinational (Malaysia, India, Sweden, USA) consortium on the special challenges raised in the concurrent management of HIV/TB co-infection due to complex drug interactions, overlapping toxicities and tuberculosis-associated IRIS. Several hypotheses are presented on the reasons for this exacerbation of tuberculosis pathogenesis by HIV and vice-versa.